Tetra Radar · FDA Approvals · Decision date

BridgeBio Pharma, Inc.: FDA decision date

BridgeBio Pharma, Inc. (BBIO) · 8 May 2027

The FDA accepted our NDA for filing, granted Priority Review and assigned a PDUFA target action date of May 8, 2027, for encaleret.

Source: 10-Q of 29 October 2026

The decision is pending.

A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.

Get the Dispatch free.